What Is Antibody-Drug Conjugate (ADC) Therapy, and How Is It Different From Immunotherapy?

What This Article Covers

Antibody-drug conjugates (ADCs) are one of the fastest-growing classes of cancer drugs, with more than a dozen now FDA-approved and several delivering some of the strongest survival data seen in recent oncology trials. Because ADCs use antibodies — the same molecular tool immunotherapy uses — they're frequently lumped in with checkpoint inhibitors, CAR-T, and bispecific antibodies in casual conversation and even some news coverage. That's a meaningful mix-up: an ADC is, at its core, a precision-guided chemotherapy delivery system, not a treatment that reprograms or unleashes the immune system. This article explains how ADCs actually work, walks through three real, currently approved ADCs and what their trial data show, and lays out exactly where the mechanistic line between ADCs and true immunotherapy falls — including the places where the two approaches genuinely do overlap.

How an ADC Actually Works

Every ADC is built from three linked parts, sometimes described as "smart chemotherapy" or a biological "guided missile": a monoclonal antibody engineered to recognize a protein (antigen) found mainly on cancer cells; a potent cytotoxic drug payload, often far too toxic to give as ordinary chemotherapy; and a chemical linker holding the two together. The antibody circulates through the bloodstream, binds its target antigen on the tumor cell surface, and the whole complex is pulled inside the cell. Once internalized, the linker breaks down and releases the payload, which kills the cell from within. Many ADCs also produce a "bystander effect," where released payload leaks into and kills neighboring tumor cells that lack the target antigen — useful in tumors with uneven antigen expression. Because the drug is concentrated inside antigen-positive cells rather than circulating freely through the whole body the way conventional chemotherapy does, ADCs can use more potent payloads while sparing more healthy tissue — though, as the safety data below show, they are far from side-effect-free.

ADCs vs. True Immunotherapy: The Key Distinction

True immunotherapies — checkpoint inhibitors, CAR-T cell therapy, and bispecific antibodies — work by mobilizing or redirecting a patient's own immune system to recognize and destroy cancer. An ADC does something categorically different: it uses an antibody purely as a delivery vehicle for a cytotoxic drug, killing tumor cells directly through chemotherapy, the same way traditional chemotherapy does, just aimed more precisely. As one patient-education overview puts it plainly, immunotherapy antibodies "alert the immune system to initiate an attack," while an ADC's antibody instead carries a chemotherapy "warhead" straight into the cancer cell. That said, the line isn't perfectly clean. Because ADCs still use full antibodies with an intact Fc region, some can trigger secondary immune-mediated killing mechanisms — antibody-dependent cellular cytotoxicity (recruiting natural killer cells), antibody-dependent phagocytosis, and complement activation — alongside their direct chemotherapy effect. So an ADC's antibody component can incidentally engage parts of the immune system even though its primary, defining mechanism is direct cytotoxic drug delivery, not immune activation.

What the Evidence Shows for Approved ADCs

Three ADCs illustrate how far this class has come, each with FDA approvals confirmed through 2026. Trastuzumab deruxtecan (Enhertu), targeting HER2, has expanded well beyond its original metastatic breast cancer approval. In May 2026, the FDA approved it for two new early-stage HER2-positive breast cancer settings: as neoadjuvant therapy (given before surgery) and as adjuvant therapy for patients with residual disease after surgery. In the neoadjuvant DESTINY-Breast11 trial, adding Enhertu produced a pathological complete response rate of 67.3%, compared with 56.3% on the prior standard regimen. In the adjuvant DESTINY-Breast05 trial, it lowered the three-year risk of invasive disease recurrence dramatically — 92.4% of patients were disease-free at three years versus 83.7% on the prior standard, ado-trastuzumab emtansine.

Sacituzumab govitecan (Trodelvy), targeting Trop-2, received FDA approval in June 2026 for first-line metastatic triple-negative breast cancer — both as monotherapy for patients ineligible for checkpoint inhibitors, and in combination with pembrolizumab for PD-L1-positive tumors. In the ASCENT-04/KEYNOTE-D19 combination trial, median progression-free survival reached 11.2 months versus 7.8 months with chemotherapy plus pembrolizumab alone.

Enfortumab vedotin (Padcev), targeting Nectin-4, is FDA-approved for locally advanced or metastatic urothelial (bladder) cancer, including in combination with pembrolizumab as first-line therapy. Its approval history has continued to expand into earlier disease stages, including a July 2026 approval for neoadjuvant and adjuvant use in muscle-invasive bladder cancer regardless of a patient's eligibility for cisplatin chemotherapy — broadening access to a group of patients who previously had fewer options.

Side Effects and Limitations

ADCs are not simply "gentler chemo." Because the payload is genuinely cytotoxic, real toxicities remain, and some are payload-specific. Trastuzumab deruxtecan carries a boxed warning for interstitial lung disease (ILD)/pneumonitis; a pooled analysis of monotherapy trials found drug-related ILD in 15.4% of patients, with the large majority low-grade but a small fraction (2.2%) fatal, underscoring the need for proactive monitoring. Other ADCs carry their own signature risks — peripheral neuropathy, ocular toxicity, or low blood counts and infection risk, depending on the linked drug. These are chemotherapy-class toxicities, not the immune-related adverse events (like colitis or thyroid dysfunction) typically seen with checkpoint inhibitors — another practical reminder that ADCs and immunotherapy are mechanistically, and clinically, distinct.

Bottom Line

Antibody-drug conjugates deserve their own category in any honest discussion of modern cancer treatment. They share immunotherapy's use of engineered antibodies and are often approved and used alongside checkpoint inhibitors, but their core mechanism is direct: an antibody delivers a potent chemotherapy payload straight to the tumor cell, not an immune-system reprogramming effect. For patients with HER2-positive breast cancer, triple-negative breast cancer, or urothelial cancer, that targeted delivery has translated into genuinely encouraging trial results — higher response rates, longer progression-free survival, and in Enhertu's adjuvant setting, a substantial reduction in recurrence risk. Those gains come with real, sometimes serious toxicities that require careful monitoring, so understanding an ADC for what it mechanistically is — precision chemotherapy, not immunotherapy — helps set accurate expectations for both its benefits and its risks.